arrow
S

Shinichi Oka

Japan Institute for Health Security
H指数:58
被引数:1.4万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Unanticipated global emergence and evolution of Pneumocystis jirovecii mutations and resistance driven by a human-targeted drug

由靶向人类药物驱动的肺孢子菌突变和耐药性的全球意外出现与演化

2026-09-160
PRE
Month 12 outcomes of switching to long-acting cabotegravir plus rilpivirine with an oral lead-in versus continuing bictegravir/emtricitabine/tenofovir alafenamide in the Phase 3b randomized SOLAR study

SOLAR三期b阶段随机对照研究中,换用长效卡博格韦与利匹韦林联合口服引导方案(oral lead-in)与继续使用毕克格韦/恩曲他滨/替诺福韦艾拉酚胺方案后的12个月结局。

2025-12-010
OAAI
HIV-1-specific CD8+ T cells with different abilities to recognize HIV-1-infected cells in HIV-1-exposed seronegative individuals

HIV-1特异性的CD8+ T细胞,在HIV-1暴露但血清阴性的个体中,具有不同识别HIV-1感染细胞的能力

2025-11-010
PRE
Preinfection Neutralizing Antibodies, Omicron BA.5 Breakthrough Infection, and Long COVID: A Propensity Score-Matched Analysis
2023-09-265
OA
Efficacy, safety, and tolerability of switching to long-acting cabotegravir plus rilpivirine versus continuing fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed adults with HIV, 12-month results (SOLAR): a randomised, open-label, phase 3b, non-inferiority trial

在病毒学抑制的HIV成人患者中,转换为长效卡博特韦加利皮韦林与持续固定剂量的比替格韦,恩曲他滨和替诺福韦艾拉酚胺的疗效,安全性和耐受性,12个月的结果 (SOLAR): 一项随机,开放标签,3b期,非劣效性试验

2023-09-0126
PRE
Combination of Amoxicillin 3000 mg and Probenecid Versus 1500 mg Amoxicillin Monotherapy for Treating Syphilis in Patients With Human Immunodeficiency Virus (HIV): An Open-Label, Randomized, Controlled, Non-Inferiority Trial
2023-05-099
PRE